Coronary Artery Disease Clinical Trial
— DRC-04Official title:
A Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Dose-dependent Effect of Colchicine on Inflammatory Response and Endothelial Function in Type 2 Diabetic Patients With Coronary Artery Disease and Leukocyte Activation
NCT number | NCT03376698 |
Other study ID # | 1195 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 15, 2017 |
Est. completion date | April 1, 2022 |
Verified date | May 2022 |
Source | University of the Ryukyus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to investigate dose-dependent effects of low dose colchicine on inflammatory responses, endothelial function in type 2 diabetic patients with coronary artery disease and leukocyte activation. This study also tested the relationship between doses and safety issue such as incidence of diarrhea. Eligible patients will be randomly allocated to three treatment group: colchicine at 0.5mg per day, 0.25mg per day or placebo for 12 weeks in a double blind , parallel group design. High sensitive-CRP at 4 weeks as primary end point and flow mediated vasodilatation at 12 weeks as the secondary end point will be measured.
Status | Completed |
Enrollment | 54 |
Est. completion date | April 1, 2022 |
Est. primary completion date | March 4, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - The subjects in this trial must have all of the following criteria. 1. Patients with type 2 diabetes mellitus with coronary artery disease(*1) with increased inflammatory response(*2). - 1:"Type 2 diabetes" mellitus is diagnosed by criteria according to The Japan Diabetes Society. "Coronary artery disease" is defined as having equal to or greater than 75% stenosis in coronary angiography, history of acute coronary syndrome, and history of coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). - 2:"Increased inflammatory response" is defined as follow; White blood cell levels at confirmation tests of eligibility is equal to or greater than 7000 /µL. 2. Patients aged 20 years and older 3. In female subjects who had possibility of pregnancy and male subjects who had female partner who had possibility of pregnancy and not undergone a contraceptive surgery(*3), patients with consent of performing optimal contraception from starting study drug to 90 days from final taking. - 3: Male subjects who had undergone a contraceptive surgery are defined as elapsing for at least one year after vasectomy and having a certification of no sperm at ejaculation. 4. After receiving sufficient explanation for the participation of this study, patients who wrote document of informed consent by the patient's free will with sufficient understanding. Exclusion Criteria: - The subjects who conflict with at least one of the following criteria are exclude from this trial. 1. Patients with prior hypersensitivity to Colchicine. 2. Patients with taking Colhicine presently or to 30 days before confirmation tests of eligibility. 3. Patients with liver cirrhosis 4. Patients with clinical cholestasis. 5. Patients with decreasing renal function (eGFR < 30 mL/min/1.73m2) at confirmation tests of eligibility. 6. Patients with active malignancy. 7. Patients taking drugs that are indicated as "combined caution" in the package insert of Colchicine as a drug which may interact with Colchicine. 1. Drugs inhibiting cytochrome P450 drug-metabolizing enzyme 1. Strong Inhibitor Atazanavir, Clarithromycin, Indinavir, Itraconazole, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Telithromycin, Telaprevir, Preparation including Cobicistat 2. Moderate Inhibitor Amprenavir, Aprepitant, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Verapamil 2. P-glycoprotein inhibitor Ciclosporin 8. Patients taking Amiodarone or Quinidine. 9. Patients with infectious or inflammatory disease at confirmation tests of eligibility. 10. Current smoker 11. Patients with pregnancy, possible pregnancy, on breast-feeding or who wish to become pregnant during trial. (The female subjects who had possibility of pregnancy receive a pregnancy test.) 12. Patients registered in other clinical trials presently or within 30 days before acquisition consent of this trial. 13. Patients whom physician in charge considered inappropriate for the study. |
Country | Name | City | State |
---|---|---|---|
Japan | Hiroshima University Hospital | Hiroshima | |
Japan | Kitasato University Hospital | Kanagawa | |
Japan | Urasoe Sogo Hospital | Okinawa | |
Japan | Dokkyo Medical University Nikko Medical Center | Tochigi | |
Japan | Showa University Hospital | Tokyo |
Lead Sponsor | Collaborator |
---|---|
University of the Ryukyus |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cardiovascular events | death, myocardial infarction, stroke, hospitalization due to worsening heart failure, unstable angina | 12 weeks | |
Other | Adverse events | 12 weeks | ||
Other | Side effect | 12 weeks | ||
Other | Diarrhea | especially notable adverse event | 12 weeks | |
Other | Concentration of colhicine in plasma (ng/ml) | feasible facility only | 12 weeks | |
Other | Concentration of colhicine in white blood cell (ng/1*10^9 cells) | feasible facility only | 12 weeks | |
Primary | Change in serum high-sensitivity CRP (mg/dl) | 4 weeks | ||
Secondary | Change in serum high-sensitivity CRP (mg/dl) | 12 weeks | ||
Secondary | Change in Flow Mediated Dilatation (%) | 12 weeks | ||
Secondary | Change in adhesive ability of white blood cell (number/field of view) | 4 weeks | ||
Secondary | Change in time through the microchannel of white blood cell (sec) | 4 weeks | ||
Secondary | Change in plasma myeloperoxidase level (ng/ml) | 4 and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |